Cubist Pharmaceuticals Recalls Vials With Glass Particulate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cubist Pharmaceuticals Recalls Vials With Glass Particulate


Cubist Pharmaceuticals announced that it is voluntarily recalling four lots of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter found in a number of vials from these lots, Cubist announced in a press release.

The lots of 500-mg Cubicin in 10-mL, single-use vials were shipped between May 2011 and March 2013. An internal investigation has preliminarily identified the root cause as a manufacturing issue with a supplier, and Cubist has suspended all manufacturing with the supplier until corrective and preventative measures have been taken.

Cubist is notifying customers by letter and phone and notes that existing inventory should be checked. Cubist is arranging for return of recalled product. Glass particulate in an intravenous drug poses a potential safety risk to patients, but no adverse events related to the recall have been reported to date.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here